Pre-eclampsia. Lancet. 2010;376(9741):631-44.
(809.94 KB)
. 
Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004.
(280.12 KB)
. 
Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):449-62.
(178.71 KB)
. 
The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120.
(322.85 KB)
. 
Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada. 2011;33(5):516 - 529.
(298.54 KB)
. 
Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714.
(383.37 KB)
. 
PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.
(292.91 KB)
. 
PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.
(292.91 KB)
. 
Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.
(201.46 KB)
. 
Pre-eclampsia in low and middle income countries. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):537-48.
(309.47 KB)
. 
The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can. 2011;33(9):900-8.
(370.8 KB)
. 
Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can. 2011;33(8):803-809.
(269.78 KB)
. 
Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol. 2012;29(7):551-6.
(194.2 KB)
. 
Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol. 2012;29(7):551-6.
(194.2 KB)
. 
Improving maternal and perinatal outcomes in the hypertensive disorders of pregnancy: A vision of a community-focused approach. Int J Gynaecol Obstet. 2012;119 Suppl 1:S30-S34.
(112.74 KB)
. 
The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81.
(233.18 KB)
. 
Preeclampsia in low and middle income countries-health services lessons learned from the PRE-EMPT (PRE-Eclampsia-Eclampsia Monitoring, Prevention and Treatment) project. J Obstet Gynaecol Can. 2012;34(10):917-926.
(322.96 KB)
. 
An assessment of predictive value of the biophysical profile in women with preeclampsia using data from the fullPIERS database. Pregnancy Hypertens. 2013;3(3):166-71.
(232.97 KB)
. 
Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res. 2013;13:527.
(2 MB)
. 
Measuring maternal health: focus on maternal morbidity. Bull World Health Organ. 2013;91(10):794-6.
(660.26 KB)
. 
Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8.
(85.31 KB)
. 
Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223.
(529.81 KB)
. 
PRE-EMPT (PRE-eclampsia-Eclampsia Monitoring, Prevention and Treatment): A low and middle income country initiative to reduce the global burden of maternal, fetal and infant death and disease related to pre-eclampsia. Pregnancy Hypertens. 2013;3(4):199-202.
(183.96 KB)
. 
Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013;(4):CD004351.
(447.63 KB)
. 
Random urine albumin:creatinine ratio in high-risk pregnancy - Is it clinically useful?. Pregnancy Hypertens. 2013;3(2):112-4.
(189.28 KB)
. 
Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61(5):932-42.
(529.57 KB)
. 
Unexpected random urinary protein:creatinine ratio results-limitations of the pyrocatechol violet-dye method. BMC Pregnancy Childbirth. 2013;13:152.
(834.74 KB)
. 
34 weeks of gestation-lost in translation. J Obstet Gynaecol Can. 2014;36(6):480-481.
(706.24 KB)
. 
Development of mHealth applications for pre-eclampsia triage. IEEE J Biomed Health Inform. 2014;18(6):1857-64.
(300.31 KB)
. 
Effect of magnesium sulphate on fetal heart rate parameters: a systematic review. J Obstet Gynaecol Can. 2014;36(12):1055-1064.
(1.57 MB)
. 
Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One. 2014;9(12):e113715.
(359.44 KB)
. 
Low-dose calcium supplementation for preventing pre-eclampsia: a systematic review and commentary. BJOG. 2014;121(8):951-7.
(118.31 KB)
. 
Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-163.
(1.42 MB)
. 
Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121(10):1210-8; discussion 1220.
(158.15 KB)
. 
Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62.
(317.15 KB)
. 
Pre-eclampsia: an update. Curr Hypertens Rep. 2014;16(8):454.
(486.35 KB)
. 
A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. PLoS Med. 2014;11(1):e1001589.
(353.97 KB)
. 
Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can. 2014;36(10):870-877.
(1021.64 KB)
. 
Are long-term health risks of pre-eclampsia and intrauterine growth restriction really the same?. BJOG. 2015;122(13):1824.
(33.63 KB)
. 
Assessing the incremental value of blood oxygen saturation (SpO(2)) in the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Risk Prediction Model. J Obstet Gynaecol Can. 2015;37(1):16-24.
(1.11 MB)
. 
Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens. 2015;5(4):315-21.
(505.41 KB)
. 
Diagnostic accuracy of placental growth factor and ultrasound parameters to predict the small-for-gestational-age infant in women presenting with reduced symphysis-fundus height. Ultrasound Obstet Gynecol. 2015;46(2):182-90.
(349.22 KB)
. 
Economic evaluation of Community Level Interventions for Pre-eclampsia (CLIP) in South Asian and African countries: a study protocol. Implement Sci. 2015;10:76.
(1.88 MB)
. 
The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia: An exploratory, randomized placebo controlled study. Pregnancy Hypertens. 2015;5(4):273-9.
(318.08 KB)
. 
Genome-wide DNA methylation identifies trophoblast invasion-related genes: Claudin-4 and Fucosyltransferase IV control mobility via altering matrix metalloproteinase activity. Mol Hum Reprod. 2015;21(5):452-65.
(1007.58 KB)
. 
The hypertensive disorders of pregnancy (29.3). Best Pract Res Clin Obstet Gynaecol. 2015;29(5):643-57.
(227.04 KB)
. 
Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015;14(3):453-61.
(463.16 KB)
. 
Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(24):2367-8.
(515.75 KB)
. 
Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres. J Obstet Gynaecol Can. 2015;37(11):975-87.
(362.1 KB)
. 
Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. BMC Pregnancy Childbirth. 2015;15:347.
(549.75 KB)
. 